Key facts
- This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Apr 2024, 18:59.
Michael Egholm - 05 Jan 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- LAB
- Reported as of
- 05 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Apr 2024, 18:59:07 UTC
- Prior SEC filing
- 06 Apr 2023
- Next SEC filing
- 09 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Egholm by Agnieszka Gallagher, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Egholm filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 05 Apr 2024.
Change
- Previous filing in this sequence was filed on 06 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LAB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +9,006
- Change %
- +4.2%
- Price
- $0.000000
- Shares after
- 225,518
- Date
- 05 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
LAB
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +196,512
- Change %
- +87%
- Price
- $0.000000
- Shares after
- 422,030
- Date
- 04 Apr 2024
- Ownership
- Direct
LAB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +212,126
- Change %
- +50%
- Price
- $0.000000
- Shares after
- 634,156
- Date
- 05 Apr 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LAB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -196,512
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 393,025
- Date
- 04 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 196,512
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Received in exchange for 8,114 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Issuer"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Issuer's common stock at the effective time of the Merger.
Footnote F2
On April 11, 2023, the Reporting Person was granted a target amount of 231,579 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 212,126 RSUs as of March 31, 2024.
Footnote F3
Each RSU represents the contingent right to receive one share of the Issuer's common stock.
Footnote F4
On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.